Compare UGP & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UGP | GRFS |
|---|---|---|
| Founded | 1937 | 1940 |
| Country | Brazil | Spain |
| Employees | N/A | 25247 |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.8B |
| IPO Year | 2001 | N/A |
| Metric | UGP | GRFS |
|---|---|---|
| Price | $5.22 | $7.61 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | $5.05 | ★ $10.15 |
| AVG Volume (30 Days) | ★ 2.7M | 775.0K |
| Earning Date | 03-05-2026 | 07-28-2022 |
| Dividend Yield | ★ 4.25% | 1.88% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.57 | $5.33 |
| Revenue Next Year | $5.90 | $6.50 |
| P/E Ratio | ★ $9.99 | $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.71 | $6.19 |
| 52 Week High | $5.42 | $11.14 |
| Indicator | UGP | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 58.23 | 30.78 |
| Support Level | $3.71 | N/A |
| Resistance Level | $5.34 | $9.11 |
| Average True Range (ATR) | 0.16 | 0.21 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 86.81 | 7.39 |
Ultrapar Participacoes SA engages in the investment of its own capital in services, commercial, and industrial activities, through the subscription or acquisition of shares of other companies. The company's business segments include: i) Ultragaz distributes LPG in the segments: bulk, comprising condominiums, trade, services, industries, and agribusiness; and bottled, mainly comprising residential consumers. ii) Ipiranga, the majority revenue generating segment, engages in the distribution and sale of oil-related products to service stations that operate under the Ipiranga brand throughout Brazil. iii) Ultracargo operates in specialized liquid bulk storage solutions in the main logistics centers. iv) Hidrovias: operates in logistics solutions and waterway and multimodal infrastructure.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.